Stem cell therapy for refractory angina

Sharven Taghavi, Jason M. Duran, Jon C. George
Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

Stem cells (SC) have demonstrated significant potential for regeneration of ischemic myocardium in both animals and humans, primarily after acute myocardial infarction. Recently, SC therapy for unstable angina pectoris, to include intractable chest pain and non-revascularizable coronary disease, has displayed clinical benefit within this subset of patients that are often refractory to medical therapy and poor candidates for reperfusion strategies, and thereby urgent need for novel therapies. Few human clinical trials have been completed to date with positive yet variable results due to inconsistencies in trial design rendering them difficult to interpret for clinical practice. Herein, a summary of all clinical trials of SC therapy in refractory angina is provided with pertinent findings from each study.

Introduction

There is increasing evidence that stem cells (SC) can be an effective therapy for regeneration of ischemic myocardium. Numerous clinical trials have shown an improvement in cardiac function with the administration of SC after acute myocardial infarction. However, SC therapy in patients with unstable angina pectoris (Figure 1), to include intractable chest pain and non-revascularizable coronary disease, has only been sparsely studied. Since these patients are often refractory to medical therapy and poor candidates for reperfusion strategies, there is immense need for novel therapies.

Preclinical animal studies have demonstrated that injection of SC, obtained from autologous bone marrow (BM), into ischemic areas in chronic myocardial infarction (MI) models results in improved cardiac function and increased vascularity. The proposed mechanisms behind these findings are angiogenesis and improved collateral circulation in the ischemic area. There is evidence to support that BM releases factors such as vascular endothelial growth factor (VEGF) and choriogonadotropic membrane (CAM) that promote vascularity. Furthermore, there is data to suggest that injected BM-SC can lead to regeneration of infarcted myocardium by differentiating into a variety of cells including myocytes, endothelium, and smooth muscle cells. These findings have led to a number of clinical trials geared towards establishing the safety and efficacy of SC therapy as a last resort in patients with refractory angina pectoris.

Majority of SC studies for refractory chest pain have primarily used autologous adult BM cells, although other sources such as peripheral blood and umbilical cord blood have also been evaluated. However, due to the low risk of rejection as compared to umbilical cord blood SC and the high yield of cells as compared to peripheral blood SC, adult BM-SC have prevailed as the most popular source. Human trials for chronic MI have also evaluated various methods of SC delivery, with the most common being direct intramyocardial (IM) injection with and without indirect mobilization of stem cells using granulocyte-colony stimulating factor (G-CSF). Alternate methods of delivery include intracoronary (IC) infusion, transcoronary sinus (TCS) infusion, and transmyocardial laser revascularization (TMLR) with direct IM injection.

Direct intramyocardial injection

The safety and feasibility of IM injection of SC (Figure 2) in patients with refractory angina via cardiac catheterization has been established in multiple non-randomized trials as summarized in Table 1. Tse et al. first reported it in eight patients with no adverse effects. These patients were followed for only three months and demonstrated a reduction in anginal symptoms despite no significant improvement in left ventricular ejection fraction (LVEF). In addition, the study revealed a decrease in percentage of ischemic myocardium as compared to baseline after three months. Subsequently, Brigouri et al. studied nine patients who were not eligible for revascularization and showed improvement in anginal symptoms within one year of follow up. Moreover, half of these patients demonstrated decreased severity and extension of ischemic area. Fuchs et al. administered BM-SC via IM injection to 27 patients with un-revascularizable coronary disease, showing an improvement in anginal symptoms and improved stress-induced perfusion scores at one year. Additionally, this study compared characteristics of BM-SC administered to responders and non-responders and found that there was no statistically significant difference in cellular composition including percentage of CD34-
### Table 1. Summary of clinical trials using stem cell therapy for refractory angina.

| Study | Trial design | Groups (n) | Cell type | Cell count | Follow up (months) | Primary end point | Change in EF primary end point |
|-------|--------------|------------|-----------|------------|--------------------|-------------------|--------------------------------|
| Tse et al. | NRNC | BM Intramyocardial injection (8) | BM (mononuclear cells) | Unspecified (3.2% CD34<sup>+</sup>) | 3 | MRI wall thickening | Improvement in wall thickening by 11.6% |
| Briguori et al. | NRNC | BM Intramyocardial injection (10) | BM (mononuclear cells) | 32.6x10<sup>6</sup> (4.6x10<sup>6</sup> CD34<sup>+</sup>/CD45<sup>+</sup>) | 12 | Ischemic area by SPECT and PET | Decreased severity and extension of ischemic area in 4 of 8 patients |
| Fuchs et al. | NRNC | BM Intramyocardial injection (27) | BM (mononuclear cells) | 28x10<sup>6</sup> (2.4% CD34-containing) | 12 | Stress myocardial perfusion score by SPECT (3 mos) CCS angina score (1 year) | Improved stress induced perfusion score from 2.2 to 1.7 Improvement of CCS from 3.2 to 2.2 |
| Beeres et al. | NRNC | BM Intramyocardial injection (25) | BM (mononuclear cells) | 84x10<sup>6</sup> | 12 | Stress myocardial perfusion score by SPECT | Ischemic segments decreased from 4.7 to 1.6 |
| Tse et al. | RC | BM Intramyocardial injection (10, 9) | BM (mononuclear cells) | 2x10<sup>6</sup> (0.79x10<sup>6</sup>CD34<sup>+</sup>) | 6 | Exercise treadmill time | Increase in exercise time from 393 s to 464 in BM treated group Decrease in exercise time from 439 to 383 in control group |
| Ramshorst et al. | RC | BM Intramyocardial injection (24) | BM (mononuclear cells) | 100x10<sup>6</sup> | 6 | Stress myocardial perfusion score by SPECT | Improved summed score from 23.5 to 20.1 in BM group Improved summed score from 24.8 to 23.7 in PL group |
| Losardo et al. | RC | BM Intramyocardial injection + GM-CSF (6,6,6) | BM (CD34<sup>+</sup> cells only) | 5x10<sup>6</sup> | 6 | Angina Frequency/ Nitroglycerin Use | Improvement of angina in groups that received combination therapy |
| Vicario et al. | NRNC | BM Transcoronary Sinus Infusion (15) | BM (mononuclear cells) | 0.08x10<sup>6</sup>/kg | 12 | CCS angina score, stress myocardial perfusion by SPECT, Coronary Angiography | Improvement of CCS from 3.0 to 1.6, Improvement in stress summed score from 19.9 to 13.6, More collaterals on angiography |
| Reyes et al. | NRNC | Transmyocardial Laser Therapy + BM Intramyocardial injection (14) | BM (mononuclear cells) | 81.3x10<sup>6</sup> (0.6x10<sup>6</sup> CD34<sup>+</sup>/CD133<sup>+</sup>) | Mean of 7 months | CCS angina score | Improvement of CCS from 3.2 to 1.4 |

RC, randomized controlled; NRNC, non-randomized non-controlled; BM, bone marrow; PL, placebo.
cells and rates of growth factor secretion.\textsuperscript{9} Beeres \textit{et al.}\textsuperscript{9,10} further described improvement in quality of life (QOL) scores and stress-induced perfusion scores in patients receiving BM-SC via IM injection after one year. All of these studies were carried out without any adverse outcomes attributable to the intervention.

The first randomized controlled trial involving IM injection of BM-SC for refractory chest pain, PROTECT-CAD,\textsuperscript{11} enrolled 19 patients in the experimental group, which had low-dose (9 patients) and high-dose (10 patients) subgroups depending on the number of BM-SC delivered, and an additional 9 patients in the control group, that received placebo injections, followed for a total of 6 months. Targeted SC injection was performed using the Myostar catheter (Biosense-Webster Inc., Diamond Bar, CA, USA) after left ventricular electro-mechanical mapping using the NOGA catheter (Biosense-Webster Inc.). Compared with the control group, patients that received SC therapy showed a statistically significant progression in exercise treadmill time, increase in ejection fraction (+5.4\%) after 6 months, and improvement in New York Heart Association (NYHA) functional class. Canadian Cardiovascular Society (CCS) survey score decreased similarly in both experimental and control groups. There was no statistically significant difference in total exercise time between the low and high-dose groups and improvement was not found to be correlated with quantity of BM-SC delivered.

The largest randomized controlled trial to date published by Ramshorst \textit{et al.}\textsuperscript{12} was carried out using 50 patients with the primary outcome being 17-segment score in a stress myocardial perfusion study. Electromechanical mapping and IM SC delivery was again performed using the NOGA and Myostar catheters. This study followed patients for only 6 months with stress myocardial perfusion studies and left ventricular function being assessed at only 3 months. There was significant improvement in the summed stressed perfusion score at 6 months and ejection fraction at 3 months in the experimental group while no change was seen in the control group. Moreover, CCS and QOL scores were also significantly higher at 6 months in the experimental group as compared to controls.

The treatment of patients with refractory angina using IM injection of SC has demonstrated improvement of anginal symptoms and increased perfusion of chronically ischemic myocardium in multiple trials carried out to date,\textsuperscript{6-12} of which only two are randomized-controlled trials\textsuperscript{11,12} with the largest trial enrolling only 50 patients.\textsuperscript{12} The variability in findings among these studies are likely due to the disparity in study design (differing end points, follow up times, quantity of cells delivered, and composition of cells delivered): More long-term trials are needed as the longest follow up is for 12 months. The upcoming FOCUS (First Mononuclear Cells injected in the US) trial\textsuperscript{13} will examine transendocardial delivery of SC in a randomized, controlled trial where isolated BM-SC will be delivered using the NOGA and Myostar catheters and followed for 5 years. The clinical endpoints include change in maximum oxygen consumption, left ventricular end systolic volume as measured by echo, and change in ischemic defect size as assessed by single-photon emission computed tomography (SPECT). This trial will present long-term data regarding the efficacy of IM injection of BM-SC.

**Combination of indirect mobilization and direct intramyocardial injection**

Animal models have shown that cytokines can be used to induce mobilization of BM-SC (Figure 3) in infarcted myocardium\textsuperscript{14} resulting in increased angiogenesis and coronary collateralization.\textsuperscript{15} The end result in animal MI models has been improved left ventricular function and survival.\textsuperscript{10} While many clinical trials exist examining the use of cytokine therapy, most commonly G-CSF in acute MI, no clinical trials have yet been performed using cytokine therapy alone for refractory angina. Animal models have also displayed an improvement in cardiac function in chronic MI models treated with VEGF secondary to improved angiogenesis in ischemic myocardium.\textsuperscript{16} However, no clinical trials evaluating the use of VEGF in unstable angina pectoris in humans have been completed.

There has been a single randomized controlled trial by Losordo \textit{et al.},\textsuperscript{17} examining combination therapy of G-CSF and IM injection of SC, with one group receiving IM CD34\textsuperscript{+} BM-SC and subcutaneous G-CSF, but the other group receiving only subcutaneous G-CSF. Improvements were observed in frequency of angina

---

**Figure 2. Direct intramyocardial (transendocardial) injection.** Image showing the inside of the left ventricle. An injection catheter is passed into left ventricle using flouroscopy and stem cells are injected transendocardially into the ischemic myocardium (shaded).

**Figure 3. Administration of exogenous granulocyte-colony stimulating factor (G-CSF) mobilizes quiescent hematopoietic stem cells (HSCs) from the bone marrow to peripheral circulation.** Mobilized HSCs home to damaged tissues, where they mediate neovascularization and improve symptoms of unstable angina. Magnified on the left is an HSC, showing the G-CSF receptor/ligand interaction, and CD34, a surface marker signifying pluripotency in the vascular lineage.
symptoms, CCS angina scores, nitroglycerine use, and exercise time at 3 and 6 months in the combination group. SPECT perfusion imaging was also done but the findings were inconsistent: the automated summed perfusion scores improved in both groups, but those receiving combination therapy showed greater improvement; and visually estimated summed perfusion scores were slightly better in the combination group at 3 months but then better in the G-CSF only group at 6 months.

One could conclude from this study that since the control group received only G-CSF and displayed some improvement, that there could be a role for G-CSF administration for patients with refractory unstable angina. This study did not set out to determine if administration of G-CSF could improve ischemia in refractory chest pain as both groups received this therapy. While the improvement seen in the control group cannot be attributed solely to G-CSF administration, the group that received G-CSF without SC therapy did show improvements in angina symptoms, CCS angina scores, and exercise time as compared to their baseline values. One could also hypothesize that G-CSF administration in combination with BM-SC therapy could have a synergistic effect since patients that received the combination showed greater improvement than those that received GM-CSF alone. However, more studies are needed to prove this concept.

The authors further divided the patients receiving SC therapy into three groups based on number of CD34+ cells received and found no dose dependent difference between the three groups.

**Intracoronary injection**

A single clinical trial has been carried out examining IC injection of SC alone (Figure 4) in intractable angina, wherein Wang et al. treated 56 patients with IC infusion of BM-SC, while another 56 patients received IC injection of saline in a randomized, controlled fashion. BM-SC were isolated and selected for CD34+ cells, which were then delivered via IC infusion. This trial showed that IC injection of SC in refractory angina was safe as there were no serious adverse events, and also demonstrated efficacy, as there was a reduction in frequency of angina episodes in the experimental group. There was also improvement in nitroglycerine use, exercise time, and CCS class compared to the control group.

**Combination of indirect mobilization and intracoronary injection**

Only one trial to date has combined indirect mobilization of SC with IC injection. In the GAIN I (G-CSF in Angina patients with IHD to stimulate Neovascularization) trial, patients were pre-treated with G-CSF for 6 days and subjected to exercise stress tests at day 4 and 6 of G-CSF therapy in order to activate myocardial chemokine expression and chemokine-mediated homing of mobilized progenitors to the ischemic myocardium. At the 3rd month follow-up, these patients displayed improvement in angina frequency score and physical limitation scores, although 4 out of 20 patients had to be withdrawn from the study due to adverse events. At 3 months, all patients received a second treatment of G-CSF followed by leuakapheresis of peripheral blood. Ten of these patients were randomized to receive IC infusion of CD133+ enriched leuakapheresis product, while the other 6 patients received leuakapheresis product without cell enrichment. Three months after this intervention (6 months after enrollment), the patients continued to show improvement in angina frequency and physical limitation scores. While this study showed efficacy, it was marked with a high number of adverse events with 4 troponin-positive events and 2 episodes of thrombocytopenia. Moreover, there was no improvement seen on technetium Tc-99m sestamibi imaging at 6 months and no additional benefit in the group receiving CD133+ enriched cells.

**Transcoronary sinus administration**

Only one clinical trial has been completed studying the administration of autologous BM-SC via TCS infusion (Figure 5). This method of SC delivery was initially shown to improve cardiac function in a porcine model. In the human trial published by Vicario et al., 15 patients received autologous BM-SC via TCS delivery in a non-randomized, non-controlled fashion. TCS delivery was performed using percutaneous cannulation and subsequent SC delivery over 5 minutes during balloon occlusion of the coronary sinus for 15 minutes. At one year, patients improved QOL scores and CCS angina scores; 12 of 15 patients displayed an improvement in perfusion imaging; and 10 of 15 patients showed more collateral vessels on angiography. No other clinical trials have examined this route of SC administration.

**Transmyocardial laser revascularization and intramyocardial injection**

TMLR therapy for patients with ischemic coronary artery disease not amenable to revascularization (Figure 6) has been shown to be superior to maximal medical therapy in randomized trials. The synergistic effects of TMLR and BM-SC therapy was evaluated in 14 patients by Reyes et al. in a non-randomized fashion with an average follow up of 7 months. TMLR and SC injections were carried out through a surgical left antero-lateral thoracotomy incision at the fifth intercostal space and a Phoenix combination delivery system (Cardiogenesis Corp., Irvine, CA, USA) used to create laser channels in the ischemic myocardium and simultaneously inject SC into the border zones of these channels. The authors observed a significant improvement in angina class scores, which was the primary outcome measured after the intervention. No imaging modalities were used to assess degree of ischemia in this study.

![Figure 4. Intracoronary administration of stem cells for unstable angina.](image1)

The diagram shows only the ventricles and their circulation: the right coronary artery, the left anterior descending coronary artery, and the left circumflex artery. For stem cell delivery to the afflicted vessels, an over-the-wire balloon angioplasty catheter is advanced into the coronary artery. The stem cells are then infused into the coronary circulation and can aid in the revascularization of ischemic myocardium.

![Figure 5. Retrograde perfusion of the coronary venous sinus.](image2)

The diagram shows only the ventricles and their circulation: the right coronary artery (RCA), the left anterior descending coronary artery, the left circumflex artery, the great and middle cardiac veins, and the anterior interventricular vein (AIV). For stem cell delivery, an over-the-wire balloon angioplasty catheter is advanced into the superior vena cava or into the inferior vena cava (not shown). The balloon is inflated and cells are infused under pressure retrograde to coronary venous drainage. Cells flow through the CVS to the GCV on the posterior left ventricle, finally entering the AIV on the anterior wall of the left ventricle. Here, stem cells can reach the affected myocardium and aid in revascularization.
**Discussion**

Animal models have demonstrated a clinical benefit in the treatment of unstable angina pectoris with BM-SC. Clinical trials have also displayed a benefit in humans; however, very few randomized controlled studies exist as outlined in Table 1. Moreover, there has been an absence of negative published data on SC therapy in refractory angina and no systemic reviews or meta-analyses evaluating the feasibility and value of SC therapy in this subgroup of patients to date although they are abundant within the subgroup of patients with acute MI.1

**Mechanism of action**

While it is evident from multiple small studies that direct injection of BM cells into ischemic myocardium results in a clinical benefit for patients with refractory chest pain, the mechanism of action remains unknown. Multiple theories have been proposed and supported by animal models and the mechanism of action may be multifactorial: direct effects due to acquisition of vascular or cardiac lineage and differentiation into vascular endothelium or functional cardiac myocytes;23 or indirect effects due to secretion of paracrine cytokines and angiogenic factors leading to proliferation of surrounding myocardial tissue and neovascularization.24 Direct effects may depend on the specific type of SC as well as on the local environmental niche of the endogenous tissue while indirect effects may be a result of increased expression of chemokines such as G-CSF, SDF-1, or VEGF in the ischemic myocardium. These hypotheses have been difficult to confirm in human trials since tracking cellular differentiation is particularly difficult.25

**Lineage of stem cells**

The stem cell lineage may determine its ability to differentiate into various cell types. Human trials on patients with refractory unstable angina have exclusively used adult BM-SC. However, animal models have demonstrated functional improvement in infarcted myocardium via implantation of SC from a variety of cell lines including embryonic,26 skeletal myoblasts,27 cardiac resident progenitors,28 peripheral blood,29 and umbilical cord blood.30-32 While preliminary human studies have been conducted with peripheral and umbilical cord SC in acute MI,1 no such trials exist for refractory angina.

**Characterization of stem cells**

SC composition can vary greatly based on cell-surface molecules and mode of isolation. Studies have shown that CD34+ and CD133+ cells contribute to improved neovascularization and cardiac regeneration. Compositions of administered BM myocardial laser revascularization.

**Methods of delivery**

The most common mode of SC delivery for patients with refractory angina has primarily been via transcatheter arterial injection.5-12 One study compared G-CSF administration alone with a combination of BM-SC injection and G-CSF administration.27 Other modes of delivery seen in very limited numbers include IC infusion,13 combination of indirect mobilization and IC infusion,1 TCS infusion16 and TMLR with simultaneous IM injection of BM-SC.24 Intracoronary infusion of stem cells has not been used as a mode of delivery in clinical trials for patients with unstable angina since these patients are generally not amenable to coronary revascularization and any SC administered would be unlikely to reach ischemic myocardium in contrast to clinical trials for patients with acute MI, where revascularization strategies make reperfusion of ischemic myocardium and delivery of SC feasible.1

**Timing of delivery**

Timing of SC delivery for optimal therapeutic benefit is difficult to assess as no studies have addressed this issue within this population. It may be intuitive that patients with recent onset refractory angina may respond better to SC therapy than those that have had a prolonged course due to less viable myocardium and given that these patients are generally not candidates for reperfusion strategies, timing the therapy with another necessary intervention such as angioplasty is not possible.

**Follow-up**

The timing of follow-up in clinical trials has been variable as listed in Table 1, with the longest follow-up duration being 12 months. Most studies have occurred in the past four years, rendering it difficult to accumulate long-term data. Additional information will be gathered on prolonged effects of BM-SC therapy as more time elapses since the completion of these clinical trials.

**Tracking stem cell engraftment and cellular imaging**

Human SC trials have been limited by the inability to effectively track the administered cells. The ability to image cells after their delivery would allow investigators to verify the most effective mode of delivery, confirm engraftment, and monitor the fate of these cells with much greater certainty. Current cellular imaging strategies include labeling cells with specific markers in vitro prior to transplantation or indirect labeling of cells with imaging reporter genes transduced into the cell before transplantation.31 Both methods have their limitations as neither provides both qualitative and quantitative data about the transplanted cells. Direct labeling methods use imaging modalities such as positron emission tomography (PET), SPECT, and magnetic resonance imaging (MRI), but are limited by the short half-lives of tracers.34 In addition, these imaging modalities are not sensitive enough...
to pick up individual cells in vivo in larger animal models or humans.25

Future direction

The use of SC for refractory angina lingers in infancy as very few randomized, controlled trials have been completed to date. While current data suggests that adult BM-SC can improve cardiac function in patients with refractory angina pectoris, primarily in non-revascularizable coronary disease, many questions remain to be answered: optimal technique of delivery; type of SC; method of preparation; dosage of SC; and timing of therapy. Ongoing and future clinical trials including recently completed Phase I/II studies advancing to Phase II13,17,36,37 comparing SC therapy to placebo are needed before it can become a widespread option of therapy for patients with refractory angina.

References

1. George JC. Stem cell therapy in acute myocardial infarction: a review of clinical trials. Transl Res 2010;155:10-9.
2. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-32.
3. Silva GV, Litovsky S, Assad JA, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-6.
4. Badorff C, Brandes RP, Popp R, et al. Transdifferentiation of blood derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003;107:1024-32.
5. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-8.
6. Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003;361:47-9.
7. Briguori C, Reimers B, Sarais C, et al. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J 2006;151:674-80.
8. Fuchs S, Kornowski R, Weisz G, et al. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006;97:823-9.
9. Beeres S, Bax J, Dibbets-Schneider P, et al. Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results. Am Heart J 2006;152:684.e11-6.
10. Beeres S, Bax J, Dibbets P, et al. Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia. J Nucl Med 2006;47:574-80.
11. Tse HF, Thambur S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007;28:2998-3005.
12. van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009;301:1997-2004.
13. Willerson JT, Perin EC, Ellis SG, et al. Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS1]): Rationale and design. Am Heart J 2010;160:215-23.
14. Ortic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344-9.
15. Schaper W, Ito W. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-9.
16. Lopez JJ, Laham RJ, Stamler A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998;40:272-81.
17. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase IIa double-blind, randomized controlled trial. Circulation 2007;115:3165-72.
18. Wang S, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angiina. Cardiology 2010;117:140-7.
19. Kovacij J, Macdonald P, Feneley MP, et al. Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: the G-CSF in Angina patients with IHD to stimulate neovascularization (GAIN I) trial. Am Heart J 2008;156:596-63.
20. Vicario J, Campo C, Piva J, et al. One-year follow-up of transcoronary sinus administration of autologous bone marrow in patients with chronic refractory angina. Cardiovasc Revasc Med 2005;6:99-107.
21. Cheng D, Diegeler A, Allen K, et al. Transmyocardial laser revascularization: a meta-analysis and systematic review of controlled trials. Innovations 2006;1:295-313.
22. Reyes G, Allen KB, Aguado B, Duarte J. Bone marrow laser revascularization for treating refractory angina due to diffuse coronary artery disease. Eur J Cardiothorac Surg 2009;36:192-4.
23. Rota M, Kajstura J, Hosoda T, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci USA 2007;104:17783-8.
24. Yoon YS, Wecker A, Heyd I, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005;115:326-38.
25. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989-97.
26. Min JY, Yang Y, Sullivan MF, et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 2003;125:361-9.
27. Taylor DA, Atkins RZ, Hunsprungs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998;4:929-33.
28. Dawn B, Stein AB, Urbanek K, et al. Cardiac stem cells delivered invasively traversed the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci USA 2005;102:3766-71.
29. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
30. Leor J, Guetta E, Feinberg MS, et al. Human Umbilical cord blood-derived CD34+ cells enhance function and repair of the infarcted myocardium. Stem Cells 2006;24:772-80.
31. Henning RJ, Burgos JD, Ondrovic L, et al. Human umbilical cord blood progenitor cells are attracted to infarcted myocardium and significantly reduce myocardial infarction size. Cell Transplant 2006;15:647-58.
32. Ma N, Stamm C, Kaminski A, et al. Human cord blood cells induce angiogenesis fol-
lowing myocardial infarction in NOD/scid-mice. Cardiovasc Res 2005;66:45-54.
33. George JC, Hoit BD. Imaging Stem Cells: Can We Track Their Fate? Access Medicine Updates. Available from: http://www.accessmedicine.com/updatesContent.aspx?aid=1001263
34. Love Z, Wang F, Dennis J, et al. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med 2007;48:2011-20.
35. Dousset V, Tourdias T, Brochet B, et al. How to trace stem cells for MRI evaluation? J Neurol Sci 2008;265:122-6.
36. Adler DS, Lazarus H, Nair R, et al. Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. Front Biosci (Elite Ed) 2011;3:506-14.
37. Lasala GP, Silva JA, Kusnick BA, Minguell JJ. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc Revasc Med 2011;12:29-34.